AndroBioSys
New York
About AndroBioSys
AndroBioSys, Inc. (ABS), is a biotechnology company dedicated to the development of novel treatments for prostate disease. Based on technologies developed at Roswell Park Cancer Institute, AndroBioSys is pioneering new approaches to make treatment of prostate cancer curative, not palliative. Preventing progression of prostate disease is intertwined intimately with disruption of the androgen axis. ABS performs contract research screening services for academic, biotechnology and pharmaceutical clients and develops collaborative partnerships to discover new drugs to proprietary prostate disease targets.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $500.0K
- Last round: Series Unknown (Jan 2009)
- Website: androbiosys.com
- Phone: 7168453300
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Canonical: https://fsome.com/organization/androbiosys-2170400 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.